Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor

For carcinoid tumor Inclusion Criteria: * Histologically confirmed carcinoid tumors * Newly diagnosed advanced carcinoid tumors * Measurable tumors * Chinese men and women, age ≥ 18 years * ECOG performance status ≤ 2 * Written informed consent obtained Exclusion Criteria: * Patients with either clinically apparent central nervous system metastases or carcinomatous meningitis(non-clinical symptoms with brain lesions is eligible) * Received Cytotoxic chemotherapy, immunotherapy or radiotherapy prior to enrollment * Patients with a concurrent malignancy, or history of prior malignancy within the past three years, except for basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, treated early stage (T1a) prostate cancer or treated early stage (DCIS or LCIS) breast cancer * Prior therapy with RAD001 or other mTOR inhibitors (sirolimus, temsirolimus, everolimus) * Major surgery in the past two weeks * Any medical condition resulting in \>CTC grade 2 dyspnea * Patients with recent hemoptysis associated with carcinoid tumor (\> 1 teaspoon in a single episode within 4 weeks) * Serious, severe or uncontrolled medical or psychiatric condition * Patients receiving chronic treatment with corticosteroids or another immunosuppressive agent * Patients with a known history of HIV seropositivity * Women of childbearing potential must have had a negative serum pregnancy test within 3 days prior to the administration of RAD001 * Patients who have received an investigative drug or therapy within the last 30 days For adenocarcinoma and Large cell lung cancer with significant neuroendocrine carcinoma characteristics Inclusion Criteria: * Histologically confirmed locally unresectable or advanced well differentiated （adenocarcinoma,squamous cancer and large cell lung cancer ）with significant neuroendocrine carcinoma characteristics tumors : CgA and/or Synaptophysin +(at least 10% of cells that would have to be positive ).( the pathology shows a neuroendocrine component histologically should be at least 10% of tissue within the specimen that is read as "neuroendocrine component"). * Measurable tumors * Patients with newly diagnosed advanced cancer or progressed after 1st line treatment is eligible * Chinese men and women, age ≥ 18 years * ECOG performance status ≤ 2 * Written informed consent obtained Exclusion Criteria: * Patients with either clinically apparent central nervous system metastases or carcinomatous meningitis(non-clinical symptoms with brain lesions is eligible) * Radiotherapy to primary tumor in lung lesions prior to enrollment * Patients with a concurrent malignancy, or history of prior malignancy within the past three years, except for basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, treated early stage (T1a) prostate cancer or treated early stage (DCIS or LCIS) breast cancer * Prior therapy with RAD001 or other mTOR inhibitors (sirolimus, temsirolimus, everolimus) * Major surgery in the past two weeks * Any medical condition resulting in \> CTC grade 2 dyspnea * Patients with recent hemoptysis associated with carcinoid tumor (\> 1 teaspoon in a single episode within 4 weeks) * Serious, severe or uncontrolled medical or psychiatric condition * Patients receiving chronic treatment with corticosteroids or another immunosuppressive agent * Patients with a known history of HIV seropositivity * Women of childbearing potential must have had a negative serum pregnancy test within 3 days prior to the administration of RAD001 * Patients who have received an investigative drug or therapy within the last 30 days